Combination Therapy in Indian Visceral Leishmaniasis

Banaras Hindu University

Status and phase: Completed; Phase 3

Conditions: Leishmaniasis, Visceral

Treatments: Drug: amphotericin B deoxycholate; Drug: miltefosine + Paromomycin sulfate; Drug: Liposomal Amphotericin B with Miltefosine; Drug: Liposomal Amphotericin B and Paromomycin Sulfate

Study type: Interventional

Funder types: Other

Identifiers

NCT00523965

VLCombo 07

Details and patient eligibility

About

Rationale

The overall objective of this trial is to identify a safe and effective combination, (co-administration) short course treatment for the treatment of VL which could be easily deployed in a control programme. The hypothesis is that the combination treatment is as effective or better than the 5 mg/kg single dose of AmBisome and will reduce the risk of parasite resistance occurring. Safety and tolerability should be such that the combination can be easily deployed.

Objective

The specific primary and secondary objectives are as follows:

Primary objective:

To identify a short course combination treatment regimen which is at least as effective as a single dose of AmBisome 5mg/kg

Secondary objective:

To compare safety and tolerability of the various treatments measured by vital signs, blood biochemistry, (renal and liver function tests) haematology, spontaneous and elicited adverse event reporting

Primary Endpoint:

The primary efficacy endpoint variable is parasitological clearance 2 weeks after start of treatment with no relapse during follow up and no clinical signs or symptoms of VL at 6 months post treatment.

Parasitology is only carried out at any time during follow-up or at six months post treatment if there are signs or symptoms of VL infection.

Enrollment: 624 estimated patients

Sex: All

Ages: 12 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients > 5 years old with symptoms and signs of kala-azar (fever, weight loss, splenomegaly) and parasites demonstrated by microscopy in splenic aspirate smear

Exclusion criteria

• Pregnant or breast-feeding women
• Individuals seropositive to HIV or individuals with a serious concurrent infection such as tuberculosis or bacterial pneumonia.
• Women of child-bearing age will be counseled about adequate birth control during and for three months after miltefosine treatment and provided with a satisfactory method of contra-ception.
• Granulocyte count < 1,000/mm3, hemoglobin < 5 g/dL or platelet count < 40,000/mm3
• Hepatic transaminases or total bilirubin greater than three times normal
• Serum creatinine > 2.0 mg/dL
• Prothrombin time > 5 seconds above control
• Inability of subject or guardian to provide written informed consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

624 participants in 4 patient groups

A

Experimental group

Description:

AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8

Treatment:

Drug: Liposomal Amphotericin B with Miltefosine

B

Experimental group

Description:

AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11

Treatment:

Drug: Liposomal Amphotericin B and Paromomycin Sulfate

C

Experimental group

Description:

oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days

Treatment:

Drug: miltefosine + Paromomycin sulfate

D

Active Comparator group

Description:

amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions

Treatment:

Drug: amphotericin B deoxycholate